Hydroxyurea-Associated Relapsing Polychondritis in a Patient With Myeloproliferative Neoplasm

Abstract

Get full access to this article

View all access options for this article.

References

Dion

Costedoat-Chalumeau

Sène

, et al. Relapsing polychondritis can be characterized by three different clinical phenotypes: analysis of a recent series of 142 patients. Arthritis Rheumatol. 2016;68(12):2992-3001. doi:10.1002/art.39790

Bulte

Hoegler

Kutlu

Khachemoune

Hydroxyurea: a reappraisal of its cutaneous side effects and their management. Int J Dermatol. 2021;60(7):810-817. doi:10.1111/ijd.15302

Arber

Orazi

Hasserjian

, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405. doi:10.1182/blood-2016-03-643544

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-245. doi:10.1038/clpt.1981.154

Ogimoto

Yoshida

Mizuta

Hirai

Relapsing polychondritis after treatment with PD-1 blockade. Invest New Drugs. 2022;40(2):389-391. doi:10.1007/s10637-021-01186-3

Ferrada

. Clinical manifestations of relapsing polychondritis. Accessed March 30, 2023. https://www.uptodate.com/contents/clinical-manifestations-of-relapsing-polychondritis

Barcellini

Fattizzo

Immune phenomena in myeloid neoplasms: an “egg or chicken” question. Front Immunol. 2021;12:751630. doi:10.3389/fimmu.2021.751630

Zhang

Kong

Wang

Zhang

Xuan

PD-1/PD-L1 inhibitors in patients with preexisting autoimmune diseases. Front Pharmacol. 2022;13:854967. doi:10.3389/fphar.2022.854967